Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Monte Rosa Therapeutics, Inc. (GLUE : NSDQ)

• Company Description    Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON. Number of Employees: 150

• Price / Volume Information    Yesterday's Closing Price: $22.78 Daily Weekly Monthly 20 Day Moving Average: 1,191,345 shares Shares Outstanding: 84.48 (millions) Market Capitalization: $1,924.44 (millions) Beta: 1.56 52 Week High: $25.77 52 Week Low: $4.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.20% 1.40% 12 Week 21.17% 18.20% Year To Date 45.28% 34.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 HARRISON AVENUE SUITE 900 - BOSTON,MA 02118 USA ph: 617-949-2643 fax: - ir@monterosatx.com http://www.monterosatx.com

• General Corporate Information    Officers Markus Warmuth - Chief Executive Officer and President Jennifer Champoux - Chief Operating Officer Edmund Dunn - Senior Vice President; Corporate Controller Ali Behbahani - Director Kimberly L. Blackwell - Director Peer Information Monte Rosa Therapeutics, Inc. (CORR.) Monte Rosa Therapeutics, Inc. (RSPI) Monte Rosa Therapeutics, Inc. (CGXP) Monte Rosa Therapeutics, Inc. (BGEN) Monte Rosa Therapeutics, Inc. (GTBP) Monte Rosa Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61225M102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 84.48 Most Recent Split Date: (:1) Beta: 1.56 Market Capitalization: $1,924.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.68 Price/Cash Flow: - Price / Sales: 44.80 EPS Growth vs. Year Ago Period: -178.95% vs. Previous Quarter: 18.18% Sales Growth vs. Year Ago Period: -95.04% vs. Previous Quarter: 51.38% ROE 06/30/26 - - 03/31/26 - -40.99 12/31/25 - -15.12 ROA 06/30/26 - - 03/31/26 - -25.94 12/31/25 - -9.30 Current Ratio 06/30/26 - - 03/31/26 - 9.54 12/31/25 - 6.12 Quick Ratio 06/30/26 - - 03/31/26 - 9.54 12/31/25 - 6.12 Operating Margin 06/30/26 - - 03/31/26 - -302.69 12/31/25 - -31.23 Net Margin 06/30/26 - - 03/31/26 - -302.69 12/31/25 - -31.23 Pre-Tax Margin 06/30/26 - - 03/31/26 - -307.04 12/31/25 - -32.12 Book Value 06/30/26 - - 03/31/26 - 6.19 12/31/25 - 3.58 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©